Senestech Inc
NASDAQ:SNES
Senestech Inc
Research & Development
Senestech Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Senestech Inc
NASDAQ:SNES
|
Research & Development
-$1.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Senestech Inc
Glance View
SenesTech, Inc. engages in the development and commercialization of a proprietary technology for the management of animal pest populations, primarily rat populations through fertility control. The company is headquartered in Flagstaff, Arizona and currently employs 26 full-time employees. The company went IPO on 2016-12-08. The Company’s product ContraPest, is in the pest control industry in attacking the reproductive systems of both male and female rats. ContraPest is a liquid bait containing the active ingredients four vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest has two active ingredients, including 4-VCD and triptolide. Triptolide is derived from the thunder god vine Tripterygium wilfordii, used in traditional Chinese medicines and other over-the-counter supplements. Triptolide affects the reproductive capacity of both male and female rats. VCD is an occupational chemical that selectively destroys ovarian follicles in rats. The firm also continues to research and develop enhancements to ContraPest that align with its target verticals and other potential fertility control options for additional species.
See Also
What is Senestech Inc's Research & Development?
Research & Development
-1.6m
USD
Based on the financial report for Sep 30, 2025, Senestech Inc's Research & Development amounts to -1.6m USD.
What is Senestech Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-1%
Over the last year, the Research & Development growth was -22%. The average annual Research & Development growth rates for Senestech Inc have been 5% over the past three years , -1% over the past five years .
